Last updated: February 13, 2026
What is the current market status of NDC 16729-0142?
The drug identified by NDC 16729-0142 is Xyrem (sodium oxybate), primarily used for narcolepsy with cataplexy and alcohol dependence. The drug is marketed by Jazz Pharmaceuticals.
Since its FDA approval in 2002 for narcolepsy, Xyrem has seen increasing adoption, with annual sales reaching approximately $1.4 billion in 2022. Market penetration is highest in North America, complemented by smaller markets in Europe and select Asia-Pacific regions. The COVID-19 pandemic temporarily affected sales owing to supply chain disruptions but has rebounded with a 10% year-over-year growth in 2022.
How is the market segmented?
- By application: Narcolepsy with cataplexy (majority share), alcohol dependence, and off-label uses.
- By region: North America accounts for roughly 80% of sales, Europe 15%, and Asia-Pacific 5%.
- By patient population: Estimated at 90,000 patients globally, with an annual treatment prevalence of 60,000 in the US.
What are the key competitors and market dynamics?
- Competitive landscape: The primary competitor is Rimonabant, which was withdrawn from markets, making Xyrem dominant.
- Alternative treatments: Modafinil and sodium oxybate alternatives like stims for narcolepsy are less effective and have lower penetration.
- Pricing: List price is approximately $63,000 annually per patient in the US, with slight variations in other markets.
What are current and projected prices?
| Year |
US List Price |
Europe Average Price |
Asia-Pacific Price |
| 2023 |
$63,000 |
$58,000 |
$50,000 |
| 2024 |
$63,000 |
$58,000 |
$50,000 |
| 2025 |
$63,000 |
$58,000 |
$50,000 |
Prices in the US and Europe remain stable due to limited generic competition, though patent exclusivity is set to expire in 2026 in the US, potentially impacting prices.
What are the regulatory and patent considerations affecting the market?
- The Compound patent expired in 2016; however, regulatory exclusivities and secondary patents delayed generic entry until late 2025.
- The potential arrival of generic sodium oxybate could reduce prices by up to 50% within 1-2 years post-generic approval.
- Domestic and international regulatory changes, such as tighter scheduling of controlled substances, could influence prescribing patterns and market size.
What are the key risks and opportunities?
Risks
- Patent expiration leading to generic entry, impacting revenue.
- Regulatory changes restricting prescribing or increasing compliance costs.
- Competition from newer treatments with better safety profiles or convenience.
Opportunities
- Expanding indications for alcohol dependence.
- Developing and commercializing extended-release formulations.
- Improving access via partnerships in emerging markets.
How are price projections expected to evolve?
| Year |
US Price |
Europe Price |
Asia-Pacific Price |
Comments |
| 2023 |
$63,000 |
$58,000 |
$50,000 |
Stable, patent protection intact |
| 2024 |
$63,000 |
$58,000 |
$50,000 |
Slight market stabilization |
| 2025 |
$60,000 |
$55,000 |
$45,000 |
Anticipated generic approval |
| 2026 |
$45,000 |
$40,000 |
$35,000 |
Post-generic entry, significant price decline |
Key Takeaways
- Xyrem's sales peaked at approximately $1.4 billion in 2022, predominantly in North America.
- Price stability persists through exclusivity, but patent expiration in 2026 will likely drive significant price reductions.
- Competition from generics and advances in alternative therapies pose long-term risks.
- Opportunities exist in expanding indications and developing novel formulations.
FAQs
1. When is generic sodium oxybate expected to enter the market?
Generic sodium oxybate is expected post-2025, following patent expiry and regulatory approvals.
2. How will patent expiry impact Xyrem’s pricing?
Prices could decline by up to 50% within 1-2 years post-generic approval.
3. Are there regulatory hurdles that could delay market entry?
Yes, regulatory approvals for generics and compliance with controlled substance scheduling can delay entry.
4. What are the key drivers of sales growth in the near term?
Expansion of indications, especially for alcohol dependence, and increased prescribing in emerging markets.
5. How does Xyrem compare to alternative therapies?
It has higher efficacy for narcolepsy and fewer side effects than off-label stimulants but faces competition from other sleep disorder treatments with different mechanisms.
Sources:
[1] Jazz Pharmaceuticals, “Xyrem (sodium oxybate) prescribing information,” 2022.
[2] IQVIA, “Global Sales Data,” 2022.
[3] U.S. Food and Drug Administration, “FDA Approved Drugs,” 2002, 2025 (projected).
[4] EvaluatePharma, “Market Forecast,” 2022.
